End Of The Line For Makena?

Pink Sheet infographic shows the many regulatory challenges and sponsors that the preterm birth prevention drug has endured leading up to the US FDA's proposal for market withdrawal.

More from Post-Marketing Regulation & Studies

More from Product Reviews